This Notice (1) corrects a sentence, (2) provides guidance
on reporting progress by current ACE grantees, and (3) provides guidance and
instructions on requesting funds to support Clinical Project development.

Section IV. Application and Submission Information

Center Research Agenda (Program Overview)

Research Plan (Center Research Agenda)

The FOA states “Applicants should describe the central theme
of the proposed Program and explain how the proposed Principal, Pilot, and
Collaborative Projects fit under the overarching Program theme”. This is incorrect;
applications to this FOA cannot propose Principal or Pilot Projects. Therefore,
the sentence is corrected to read “Applicants should describe the central theme
of the proposed Program and explain how the proposed Primary and Alternate Clinical
Projects and the Collaborative Project (if proposed) fit under the
overarching Program theme”

The FOA states that a Progress Report is “[r]equired for
renewal applications; not applicable for new applications”. However, all UM1
applications will be new. Therefore, applicants who are supported by the
current ACE must include within the “Research Strategy” section of the Center
Research Agenda a report on their progress during this period of support. This
information is essential for a satisfactory review of the UM1 application.

Section II. Award Information

Award Budget

The FOA states that “this FOA will fund successful
applicants up to $50,000 per year direct costs for planning further development
of successful Clinical Trial Projects." However, the FOA did not explain
where this support could be requested or budgeted. This notice amends the FOA
(a) to explain that applicants may request support for Clinical Project
development within the Administrative Core and (b) to increase the cap on
Administrative Core budget to $100,000 direct costs (from the current $50,000
direct costs) to accommodate such requests.

Applicants requesting support for Clinical Project
development should justify the costs based on their proposed Primary Clinical
Project and explain how, once development of the Primary Clinical Project is
complete, this support will be shifted to developing other Clinical Projects
with the ACE.